💨 Abstract

Biocon, an Indian biopharmaceutical firm, plans to list its biosimilars business by March 2026 and aims for double-digit market share in the U.S. for its new launches. The company plans to launch five new biosimilars in the U.S. in the upcoming fiscal year, focusing on therapy areas such as diabetes, oncology, and immunotherapy. The U.S.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖